StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Ozurdex (dexamethasone intravitreal implant) by Quarter

Ozurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Ozurdex (dexamethasone intravitreal implant): 4.3% in Q4 2025, up 2.9 pts from a year earlier.

Latest, Q4 2025
4.3%
Period ended Dec 31, 2025
Change on a year earlier
+2.9 pts
1.4% in Q4 2024
History
12 quarters
Since Q1 2023
Sources
12
Documents cited below

Where the Q4 2025 figure comes from

“|| Ozurdex | 32 | 96 | 128 | (10.4) | 14.1 | 6.9 | 10.4 | 4.3”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOzurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 20254.3%+2.9 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-4.0%-5.1 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-0.4%-8.4 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-2.4%-17.0 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 20241.4%-9.9 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20241.1%-11.7 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20248.0%-2.2 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202414.6%+2.4 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202311.3%–Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202312.8%–Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202310.2%–Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202312.2%–Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗

Cite this data

StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) (%), quarterly Q1 2023–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex-ww-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.